This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy (RPT) with Pluvicto for advanced prostate cancer, according to a study published August 8 in the Journal of NuclearMedicine. Yet whether SPECT/CT can be used to determine disease progression or response has yet to be delineated, they noted.
Moreover, the approach could help detect disease that other effective prostate cancer PET radiotracers may miss, said Heying Duan, MD, a nuclearmedicine research scientist at Stanford University, during a November 26 scientific session. You've hear a lot about PSMA. approved Ga-68 PSMA-PET and experimental Ga-68 RM2.
PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease, according to a study published February 20 in the Journal of NuclearMedicine. Images and caption courtesy of the Journal of NuclearMedicine.
Nuclearmedicine is a form of specialty medicine that uses radioactive tracers to evaluate bodily functions and to diagnose and treat a wide range of health conditions. Nuclearscans produce images of the body’s anatomy that cannot be obtained as clearly or fully with other imaging techniques.
An article in the Journal of NuclearMedicine reports findings of a multi-center retrospective study that compares bonescan with PSMA PET for initial staging of prostate cancer.
There are several types of imaging tests that physicians use to detect cancer in patients: X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound (US), NuclearMedicine, and Positron Emission Tomography (PET). Staging and Restaging If cancer is found, it is important to determine how much the cancer has spread.
Technetium-99m (Tc-99m) methyl diphosphonate (MDP) bonescans are a potentially viable noninvasive option for diagnosing calciphylaxis, according to a team at the University of Massachusetts in Worcester, MA. The team assessed the potential diagnostic utility of bonescans in calciphylaxis based on a review of the literature.
Several presenters at the Society for NuclearMedicine and Molecular Imaging's (SNMMI) 2024 meeting in Toronto shared new findings in women's studies. In addition, the mean tissue dose did not reach the maximum tolerated dose for kidney, bone marrow, or liver. Women's theranostics appears to already be on the horizon.
The primary outcome was the correct identification of the prostate cancer tumor stage, which is crucial for surgeons to determine the extent of the disease -- whether it has spread beyond the prostate gland, for instance. Out of 150 men who participated, 134 ultimately underwent radical prostatectomies (the mean age was 62 years old).
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content